PTGS2 and breast carcinoma: Although a few conflicting reports exist, high COX-2 expression has been found in the majority of breast carcinomas, ~ 63%-85% of premalignant-stage breast cancers cases (e.g., ductal carcinoma in situ), and ~ 87% of metastatic breast cancer [24–30].